TO:                  Members, Advisory Committee for Pharmaceutical Science


FROM:            Helen Winkle

                        Acting Director, Office of Pharmaceutical Science, CDER, FDA


Date:                March 7, 2003


Re:                   Errata to Memo dated February 11, 2003 regarding ACPS Meeting March 12 and 13, 2003



In the section "Bioavailability / Bioequivalence of Endogenous Drugs", the last sentence should read as follows


"Abbott Laboratories will present an overview of research it conducted on baseline correction methods for leveothyroxine sodium.  Some of Abbott's research finding were recently adopted by FDA for bioequivalence testing on levothyroxine products.  Abbott will also discuss other approaches for baseline correction."